Skip to main content
Mehow Innovative Ltd. logo

Mehow Innovative Ltd. — Investor Relations & Filings

Ticker · 301363 ISIN · CNE100005WP6 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 498 across all filing types
Latest filing 2024-04-17 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 301363

About Mehow Innovative Ltd.

https://www.mehow.com

Mehow Innovative Ltd. specializes in the design, development, and manufacturing of high-precision medical devices and components. The company focuses on advanced manufacturing technologies, particularly Liquid Silicone Rubber (LSR) molding, multi-shot injection molding, and precision plastic components. Its core product portfolio includes respiratory care solutions, drug delivery systems, surgical instruments, and specialized medical consumables. Mehow provides comprehensive contract development and manufacturing organization (CDMO) services, encompassing product design, mold engineering, and automated assembly within controlled cleanroom environments. By integrating material science with precision engineering, the company supports global medical device manufacturers in producing complex, high-performance components for critical healthcare applications.

Recent filings

Filing Released Lang Actions
关于续聘2024年度会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (auditor) for the fiscal year 2024. It details the auditor's qualifications, independence, and the approval process by the audit committee, board of directors, and supervisory board. It does not contain any financial statements or audit results themselves, but rather the procedural and governance information about the auditor appointment. The document length is 3008 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this is not the audit report itself but an announcement related to audit services. The appropriate classification is Audit Report / Information (AR), as it relates to audit information but is not a full annual report or financial statement filing.
2024-04-17 Chinese
监事会关于2024年限制性股票激励计划相关事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board's verification opinion regarding the 2024 restricted stock incentive plan of the company. It discusses compliance with laws and regulations related to stock incentive plans, qualifications of incentive recipients, and the plan's alignment with company and regulatory requirements. It does not contain financial statements or results, nor is it an announcement of a report publication. It is a regulatory compliance and governance-related document concerning stock incentives. This fits best under Regulatory Filings (RNS) as it is a compliance and supervisory opinion document that does not fit other specific categories.
2024-04-17 Chinese
广东信达律师事务所关于公司2024年限制性股票激励计划（草案）的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by Guangdong Xinda Law Firm regarding the 2024 restricted stock incentive plan (draft) of Shenzhen Meihua Chuangyi Medical Technology Co., Ltd. It extensively discusses the legal compliance, procedures, and details of the stock incentive plan, including the plan's purpose, scope, stock allocation, and legal procedures. It is not a financial report, earnings release, or announcement of voting results. It is a standalone legal opinion related to a stock incentive plan, which fits best under the category of Regulatory Filings (RNS) as it does not match other more specific categories like Capital/Financing Update or Proxy Solicitation. The document is detailed and substantive, not a brief announcement or certification. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-04-17 Chinese
2024年限制性股票激励计划（草案）摘要
Remuneration Information Classification · 95% confidence The document is a detailed plan titled "2024 Restricted Stock Incentive Plan (Draft) Summary" for Shenzhen Meihua Chuangyi Medical Technology Co., Ltd. It extensively discusses the implementation, management, stock sources, grant quantities, vesting arrangements, performance conditions, and adjustment methods of a restricted stock incentive plan. The content focuses on stock-based employee incentives, including details about the stock grant, vesting periods, performance targets, and legal compliance. This type of document is related to executive and employee compensation and stock incentive schemes, which falls under Remuneration Information filings. It is not an announcement of a report, nor a financial report, nor a regulatory filing or proxy solicitation. Therefore, the best fitting category is Remuneration Information (DEF 14A). The document length and detail confirm it is the plan itself, not just an announcement or summary.
2024-04-17 Chinese
2024年限制性股票激励计划考核管理办法
Board/Management Information Classification · 95% confidence The document is titled as a management method for the 2024 restricted stock incentive plan assessment of Shenzhen Meihua Chuangyi Medical Technology Co., Ltd. It details the assessment principles, targets, and procedures related to the company's stock incentive plan for directors, senior management, and core employees. It includes performance targets, assessment criteria, and management of results. There is no financial statement or report data, nor is it an announcement of a report publication. The content is focused on management and board-related incentive plan rules and procedures, which aligns with Board/Management Information filings. The document length is under 5,000 characters and is not a report publication announcement but a detailed policy document. Therefore, the best fit is Board/Management Information (MANG).
2024-04-17 Chinese
深圳市他山企业管理咨询有限公司关于深圳市美好创亿医疗科技股份有限公司2024年限制性股票激励计划（草案）的独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" regarding a 2024 restricted stock incentive plan for Shenzhen Mehao Chuangyi Medical Technology Co., Ltd. It contains detailed analysis and opinions on the feasibility, accounting treatment, performance assessment, and shareholder impact of the stock incentive plan. The report is prepared by an independent financial advisor firm and includes sections on the plan's main content, verification opinions, and supporting information. It is not a general annual report, earnings release, or management discussion but a specialized advisory report related to a capital incentive plan. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to company fundraising and capital structure changes through stock incentives. The document length is substantial and contains detailed substantive content, not merely an announcement or certification, so it is not RPA or RNS. Therefore, the classification is CAP with high confidence.
2024-04-17 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.